H3B-6527
H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity[1].
Product Specifications
CAS Number
1702259-66-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
FGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/H3B-6527.html
Purity
98.0
Solubility
DMSO : 2.5 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(N2CCN(CC)CC2)=CC=C1NC3=NC=NC(N(C(NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=O)C)=C3)=O
Molecular Formula
C29H34Cl2N8O4
Molecular Weight
629.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Joshi JJ, et al. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven HepatocellularCarcinoma. Cancer Res. 2017 Dec 15;77 (24) :6999-7013.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
